- Entry
- $84.30
- Now
- $86.83 +3.0%
- Target
- —
- Score
- —
Sol-Gel (SLGL) is an Israeli dermatology company whose value now rests almost entirely on one thing: a Phase 3 trial of SGT-610 (patidegib gel) for Gorlin syndrome, a rare genetic disorder that causes patients to develop large numbers of basal cell carcinomas. Topline results are guided for Q4 2026. Alongside that, it holds a licensing book (Sun Pharma, Beimei, Searchlight, Mayne, Viatris and others) paying upfronts, milestones and royalties on two already-approved topical products, Twyneo and Epsolay, which it no …
— ORIGINAL POST ·
SLGL - Sol-Gel Technologies: catalyst-driven dermatology biotech, Gorlin Phase 3 readout Q4 2026. A major 10% holder has been buying.
· r/pennystocks
· Jul 22, 2026